Irene González Caraballo¹ · Rocío Martín Lozano¹ · Roberto Jiménez Rodríguez¹ · Javier Soto Alsar¹ · Laura Ortega Morán¹ · Miguel Martín Jiménez¹ · Andrés J. Muñoz Martín¹

^{Received: 30 January 2024 / Accepted: 13 March 2024
© The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2024}

Abstract

Background Limited data exist on the prognostic significance of the chronology of VTE in patients with PDAC.
Methods Medical data and survival characteristics of patients treated for PDAC from 2019 to 2021 were retrospectively reviewed. Early VTE was defined as occurring within the three months of PDAC diagnosis.
Results 197 patients were included, 54 (27.4%) developed a VTE. Early appearance of VTE was associated with worse prognosis: median overall survival (mOS) VTE < 3 months 8.5 months (HR 1.65, 95% CI 1.11–2.46; p = 0.014), mOS VTE > 3 months 12.8 months (HR 0.78, 95% CI 0.39–1.54; p = 0.5) and mOS patients without VTE 11.4 months (95% CI 10.1–15.4). There was no significant association between the patient’s VTE risk according to the Khorana risk score (KRS) (chi2 test p-value = 0.9).
Conclusion Early VTE is a prognostic factor in PDAC, which may identify a more aggressive subtype.

Keywords VTE · Pancreatic cancer · Early thrombosis · Prognosis 

GKB-NON-2024-00205